Dementia and Cognitive Health in LGBTQ Older Adults
Session Chairs: Maria M. Corrada, Ozioma Okonkwo
- Interventions for LGBTQ Older Adults With ADRD and Their Care Partners
Karen Fredriksen-Goldsens, University of Washington, United States
- The Epidemiology of ADRD in LGBTQ Older Adults
Jason Flatt, University of Nevada, Las Vegas; University of California, San Francisco, San Francisco, United States
- LGBTQ Older Adults With Cognitive Impairment: Implications for Early Diagnosis, Treatment and Care
Sue Westwood, University of York, United Kingdom
- Sociolegal and Practice Implications of Caring for LGBTQ People With Dementia
Rosie Harding, Birmingham Law School, United Kingdom
Ethics in Dementia
Session Chairs: Frank Jessen, Carey Gleason
- Ethical and Practical Challenges in Disclosure of APOE Genotype
J. Scott Roberts, University of Michigan, United States
- Expectations and Effects of Biomarker-Based Dementia Risk Prediction in MCI — The PreDaDQual Project
Ayda Rostamzadeh, University of Cologne, Germany
- Ethical Considerations on Individualized Risk Prediction in MCI — The ABIDE Project
Jetske van der Schaar, Amsterdam UMC, Netherlands
- Amyloid Disclosure in Mild Cognitive Impairment
Jennifer Lingler, University of Pittsburgh, United States
Immunity in The Aging or Diseased Brain
Session Chairs: Sergio Ferreira, Jose F. Abisambra
- The Bidirectional Communication Between the Brain and the Systemic Immune System in Aging
Marina Lynch, Trinity College Institute of Neuroscience, Ireland
- Trem2- Independent Activity of PD-L1 Immunotherapy in Modifying Alzheimer’s Disease in Mouse Models
Michal Schwartz, Weizmann Institute of Science, Israel
- Microglial Immune Memory and Metabolic Reprogramming Modifies Amyloid Structure and Neuronal Dystrophy in Mouse Models of Alzheimer’s Pathology
Jonas Neher, German Center for Neurodegenerative Diseases (DZNE); Hertie Institute for Clinical Brain Research, Germany
Measuring Tau Accumulation and Progression
Session Chairs: Kejal Kantarci, Brad Dickerson
- Tau Progression Evidence From Tau PET Imaging
Rik Ossenkoppele, Alzheimer Center Amsterdam; Vrije Universiteit Amsterdam, Amsterdam UMC, Netherlands; Lund University, Sweden
- Pathologic Progression of Tau
Gabor Kovacs, University of Toronto, Canada
- Multi-omic Approach to Tau Accumulation and Progression
Philip De Jager, Columbia University Medical Center, United States
- Interaction of Tau With Other Pathologies
Virginia Lee, Perelman School of Medicine at the University of Pennsylvania, United States
Mechanisms of White Matter Damage
Session Chairs: Roxana Carare, Delphine Boche
- Understanding the Pathophysiology of Amyloid-Related Imaging Abnormalities (ARIA) Following Aβ Immunotherapy
James Nicoll, University of Southampton, United Kingdom
- Biomarkers of Vascular Cognitive Impairment and Dementia; Informing Disease Mechanisms
Donna Wilcock, University of Kentucky Sanders Brown Center on Aging, United States
- Trauma-Related Axonal Damage
Victoria Johnson, University Of Pennsylvania, United States
- Neuroimaging of White Matter Hyperintensities (WMH)
Joanna Wardlaw, University of Edinburgh, United Kingdom
Repurposing Drugs Targeting Glia and Inflammatory Mechanisms
Session Chairs: Linda Van Eldik, Cynthia Lemere
- Targeting solTNF to Reduce Risk and Progression of Alzheimer’s Disease and Other Dementias
Malú Tansey, University of Florida College of Medicine, United States
- Repurposing Senotlytic Therapies for Alzheimer’s Disease
Howard Fillit, Alzheimer’s Drug Discovery Foundation, United States
- Microglial Cells in AD: Good Guys or Bad Guys?
Knut Biber, AbbVie Deutschland GmbH & Co. KG, Germany
- Finding New Uses for Old Drugs in Alzheimer’s Disease
Clive Ballard, University of Exeter Medical School, United Kingdom
Towards a Precision Medicine Approach in Alzheimer’s Disease
Session Chairs: Jonathan Schott, Wiesje van Der Flier
- Blood-Based Biomarkers to Predict Current and Future Alzheimer’s Disease
Randall Bateman, Washington University in St. Louis School of Medicine, United States
- Accurate Prediction of β-Amyloid Positivity Using Risk Models and Plasma Aβ and P-tau Analyses
Sebastian Palmqvist, Lund University; Skåne University Hospital, Sweden
- Biomarker-Based Prognosis for People With Mild Cognitive Impairment
Ingrid van Maurik, Alzheimer Center Amsterda; Vrije Universiteit Amsterdam, Amsterdam UMC, Netherlands
- Organizing Mechanistic Knowledge About Neurodegenerative Diseases for the Improvement of Drug Development and Therapy
Martin Hofmann-Apitius, Fraunhofer Institute for Algorithms and Scientific Computing (SCAI), Sankt Augustin; Bonn-Aachen International Center for IT (b-it), Germany
Using Technology to Improve Access to Cognitive Assessments and Interventions
Session Chairs: Maureen Schmitter-Edgecombe, Rema Raman
- Unsupervised Online Neuropsychological Testing — The Principles
Paul Maruff, The Florey Institute of Neuroscience and Mental Health, Australia
- Socially Assistive Robots for Cognitive and Social Stimulation
Jesus Favela, CICESE Research Center, Mexico
- Testing on Mobile Devices
Simon Collinson, Savonix, Singapore
Join the Conversation #AAIC21